Drug General Information |
Drug ID |
D0LP5V
|
Former ID |
DNC006536
|
Drug Name |
LUF-5956
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C20H18N4
|
Canonical SMILES |
CC(C)C1=NC2=NC(=NC(=C2N1)C3=CC=CC=C3)C4=CC=CC=C4
|
InChI |
1S/C20H18N4/c1-13(2)18-22-17-16(14-9-5-3-6-10-14)21-19(24-20(17)23-18)15-11-7-4-8-12-15/h3-13H,1-2H3,(H,21,22,23,24)
|
InChIKey |
WOKKQPCDRVUEPM-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A3 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Rap1 signaling pathway
|
Calcium signaling pathway
|
cAMP signaling pathway
|
Neuroactive ligand-receptor interaction
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholismhsa04022:cGMP-PKG signaling pathway
|
Sphingolipid signaling pathway
|
Morphine addiction
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
NGF-independant TRKA activation
|
Adenosine P1 receptors
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Nucleotide GPCRs
|
Monoamine Transport
|
GPCRs, Class A Rhodopsin-like
|
NGF signalling via TRKA from the plasma membrane
|
GPCR ligand binding
|
GPCR downstream signaling
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
GPCRs, Other
|
References |
REF 1 | J Med Chem. 2006 May 18;49(10):2861-7.2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. |